RxDoctor Payments Data

Michaela Stephens

Family · Tuscaloosa, ALNPI 1689244030

Payments from drug & device makers

$631in general payments, 2019–2025

Across 27 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$120
  • Lilly USA, LLC$92
  • Exact Sciences$48
  • Otsuka America Pharmaceutical, Inc.$41
  • Novo Nordisk$37
  • Sanofi Pasteur Inc.$34
  • plus $258 from 11 others

What the payments were for

  • Food & beverage$631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$631 in reported general payments places this provider in the 55th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$1,019
Medicare patients
39
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide29$53,413
JanuviaSitagliptin Phosphate18$30,284
XareltoRivaroxaban17$17,290
JardianceEmpagliflozin11$15,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,860
Advair HfaFluticasone Propion/Salmeterol20$7,478
Atrovent HfaIpratropium Bromide11$5,592
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,840
SymbicortBudesonide/Formoterol Fumarate14$3,412
Novolog FlexpenInsulin Aspart12$2,629
Albuterol Sulfate HfaAlbuterol Sulfate76$2,255
Atorvastatin Calcium202$1,603
Losartan Potassium171$1,483
LantusInsulin Glargine,hum.Rec.Anlog12$1,276
Droplet Pen NeedlePen Needle, Diabetic15$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$37$53,41329 claims
MerckJanuvia$14$30,28418 claims
Boehringer IngelheimJardiance$120$15,56211 claims
GSKTrelegy Ellipta$31$13,86012 claims
AstraZenecaSymbicort$18$3,41214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,415 family providers in Alabama.

Other family in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →